Cullinan Therapeutics, Inc. announced its recent and upcoming developments in the biopharmaceutical sector, highlighting the Phase 1 study of CLN-978 for Systemic Lupus Erythematosus (SLE), which is ...
Avalo Therapeutics, Inc. has announced significant updates and financial results for 2024, highlighting a pivotal year marked by the acquisition of AVTX-009, a monoclonal antibody aimed at treating ...
- 2024 net product sales of $336.4 million - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in PSC expected to complete enrollment in second half ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback